Skip to main content

Zura Bio Limited (94E.F)

34.3Poor

ValueMarkers Composite Index

Top 1%#44,244 of 44,714
Overvalued

378% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
11.01
Safe
DCF Value
$1
Overvalued
ROIC
-74.1%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Zura Bio Limited (94E.F) — VMCI valuation read

Zura Bio Limited (94E.F) carries a VMCI composite of 34/100, 16 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 94E.F in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 94E.F insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 94E.F trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.0x leaves covenant headroom, the line to track on Zura Bio Limited's next 10-Q.

94E.F rose 0.7% over the trailing 7 days, with a -2.6% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 94E.F’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.